BioAge Labs (NASDAQ:BIOA) Trading 7.1% Higher – Should You Buy?

BioAge Labs, Inc. (NASDAQ:BIOA) shares were up 7.1% during trading on Tuesday . The company traded as high as $18.90 and last traded at $19.11. Approximately 610,777 shares were traded during mid-day trading, a decline of 41% from the average daily volume of 1,033,453 shares. The stock had previously closed at $17.85.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAge Labs in a report on Thursday, October 30th. Wall Street Zen lowered BioAge Labs from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Citigroup raised their price objective on BioAge Labs from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $15.00.

BioAge Labs Trading Up 15.9%

The firm has a market cap of $741.74 million, a price-to-earnings ratio of -13.61 and a beta of 1.38. The stock’s 50 day moving average is $11.11 and its 200 day moving average is $7.22.

BioAge Labs (NASDAQ:BIOA) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.11. The company had revenue of $2.05 million for the quarter.

Insider Buying and Selling

In other BioAge Labs news, insider Paul D. Rubin sold 68,897 shares of the company’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $10.19, for a total value of $702,060.43. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 20.82% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On BioAge Labs

Several institutional investors and hedge funds have recently modified their holdings of the business. Police & Firemen s Retirement System of New Jersey acquired a new stake in BioAge Labs in the 2nd quarter worth about $27,000. Russell Investments Group Ltd. bought a new stake in shares of BioAge Labs in the third quarter valued at approximately $27,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in BioAge Labs by 85.6% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock worth $54,000 after buying an additional 5,976 shares in the last quarter. Public Employees Retirement System of Ohio bought a new position in BioAge Labs during the 2nd quarter worth $57,000. Finally, Intech Investment Management LLC acquired a new position in BioAge Labs in the 2nd quarter valued at $60,000.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.